Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Publication ,  Journal Article
Wu, J-Q; Lu, M-P; Reed, AM
Published in: World J Pediatr
February 2020

BACKGROUND: Juvenile dermatomyositis (JDM) is a chronic autoimmune disease characteristic by inflammation of small vessels within the skin, muscle and vital organs. But the clinical features and treatment of JDM have not been fully clarified. DATA SOURCES: Databases underwent through PubMed for articles about the clinical features, myositis-specific antibodies of JDM and its treatment, and we selected publications written in English which were relevant to the topic of this review. RESULTS: Clinical features and myositis-specific antibodies may predict the severity and prognosis of disease. Although the mortality rate has been lower with traditional treatments, such as corticosteroid, intravenous immunoglobulin, and disease-modifying anti-rheumatic drugs such as methotrexate, their usages are variable. Novel biological therapies seem to be effective for refractory JDM patients, but more clinical trials are necessary. CONCLUSIONS: JDM is a sever disease of childhood. We need to better understand recent advances of JDM in the context of clinical features including skin manifestations, muscle weakness and organ damage, myositis-specific antibodies and their associated outcomes and the treatment of disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

World J Pediatr

DOI

EISSN

1867-0687

Publication Date

February 2020

Volume

16

Issue

1

Start / End Page

31 / 43

Location

Switzerland

Related Subject Headings

  • Prognosis
  • Immunoglobulins, Intravenous
  • Humans
  • Dermatomyositis
  • Child
  • Biological Products
  • Autoantibodies
  • Antirheumatic Agents
  • Adrenal Cortex Hormones
  • 1114 Paediatrics and Reproductive Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wu, J.-Q., Lu, M.-P., & Reed, A. M. (2020). Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr, 16(1), 31–43. https://doi.org/10.1007/s12519-019-00313-8
Wu, Jian-Qiang, Mei-Ping Lu, and Ann M. Reed. “Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.World J Pediatr 16, no. 1 (February 2020): 31–43. https://doi.org/10.1007/s12519-019-00313-8.
Wu, Jian-Qiang, et al. “Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.World J Pediatr, vol. 16, no. 1, Feb. 2020, pp. 31–43. Pubmed, doi:10.1007/s12519-019-00313-8.
Journal cover image

Published In

World J Pediatr

DOI

EISSN

1867-0687

Publication Date

February 2020

Volume

16

Issue

1

Start / End Page

31 / 43

Location

Switzerland

Related Subject Headings

  • Prognosis
  • Immunoglobulins, Intravenous
  • Humans
  • Dermatomyositis
  • Child
  • Biological Products
  • Autoantibodies
  • Antirheumatic Agents
  • Adrenal Cortex Hormones
  • 1114 Paediatrics and Reproductive Medicine